SnugZ USA, Inc. – FDA Warning Letter, Nov 30, 2018

On June 12, 2019, the FDA issued a Warning Letter to SnugZ USA, Inc. following an inspection from November 26-30, 2018, citing significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). The FDA determined the firm's drug products are adulterated.

Key violations include: 1. **Failure to test finished drug products:** The firm released OTC drug products (e.g., Naawk Aloe Relief Gel + Lidocaine, sunscreens) without adequate testing for active ingredient identity and strength, or for microbial attributes, lacking scientific evidence of conformance to specifications. 2. **Inadequate component testing:** The firm failed to conduct identity testing for each component and did not validate supplier test analyses, relying solely on Certificates of Analysis (COAs) for active pharmaceutical ingredients (APIs) and other raw materials. 3. **Inadequate Quality Control Unit (QCU):** The firm lacked an adequate QCU with established procedures, responsibilities, and authority, and failed to implement adequate systems for investigations, change control, annual product reviews, and drug product approval/rejection. 4. **Lack of process validation:** The firm did not validate manufacturing processes, conduct process performance qualification studies, or have an ongoing program for monitoring process control. 5. **Inadequate equipment